A TV interview with our CEO Jason Loveridge.  Jason Loveridge discusses how 4SC AG is creating a new treatment paradigm for #CutaneousTCellLymphoma (CTCL), a rare type of non-Hodgkin lymphoma that affects the skin.

Share this page:

Follow us on: